HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TLRY
Tilray Brands, Inc.
TLRY lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TLRY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
TLRY's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TLRY PE Valuation
TLRY has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TLRY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
TLRY has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over TLRY on earnings, with more consistent year-over-year improvement.
TLRY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.41 | +$22.79 |
| Q2 2026 | -$1.09 | +$23.51 |
| Q1 2026 | -$15.15 | -$4.65 |
| Q4 2025 | -$23.61 | -$20.61 |
| Q3 2025 | -$24.20 | -$21.50 |
| Q2 2025 | -$24.60 | -$21.30 |
| Q1 2025 | -$10.50 | -$5.50 |
| Q4 2024 | -$3.00 | +$19.80 |
TLRY is still losing money, but far less than before: $1.41 per share over the past year, against $58.23 at its worst in mid-2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TLRY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over TLRY on profitability, with a higher operating margin.
TLRY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $257.1M | +23% |
| Q2 2026 | $281.7M | +25% |
| Q1 2026 | $206.7M | +11% |
| Q4 2025 | $217.5M | +3.1% |
| Q3 2025 | $209.5M | +4.7% |
| Q2 2025 | $224.5M | -2.3% |
| Q1 2025 | $185.8M | -1.4% |
| Q4 2024 | $211M | +8.9% |
TLRY's revenue has grown year over year for five quarters in a row: $257M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -9.3% | -10 points |
| Q2 2026 | -5.8% | +637 points |
| Q1 2026 | -13% | +396 points |
| Q4 2025 | -10% | +9.8 points |
| Q3 2025 | 1% | +19 points |
| Q2 2025 | -643% | -636 points |
| Q1 2025 | -409% | -366 points |
| Q4 2024 | -20% | +1.5 points |
TLRY's operating margin was −9.3% last quarter, down 10 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TLRY on cash generation, producing positive trailing cash flow while its opponent burns cash.
TLRY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$16.5M | -$15.2M |
| Q2 2026 | -$37.3M | -$18.2M |
| Q1 2026 | -$21.9M | -$1.8M |
| Q4 2025 | -$8.5M | +$37.6M |
| Q3 2025 | -$1.3M | +$40.7M |
| Q2 2025 | -$19.1M | -191% |
| Q1 2025 | -$20.2M | +$4.7M |
| Q4 2024 | -$46.2M | -$9.9M |
TLRY has burned cash in almost every quarter: −$84M over the past year, against −$87M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TLRY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TLRY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +19% | +21.5M shares |
| 1 year | +26% | +27.3M shares |
| 3 years | +93% | +64.2M shares |
| 5 years | +197% | +88.4M shares |
| Available history | +1484% | +125M shares |
TLRY has 133M diluted shares, up 26% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TLRY Net Leverage
TLRY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TLRY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.0 | Oversold |
| Stochastic | 6.8 | Oversold |
TLRY's weekly RSI is 28 (oversold) and its Stochastic is 7 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TLRY PE vs Healthcare Sector
TLRY has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TLRY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.13 | 20% below |
| 20 week MA | $3.90 | 36% below |
| 50 week MA | $5.89 | 58% below |
| 100 week MA | $7.39 | 66% below |
| 200 week MA | $13.9 | 82% below |
TLRY is in a downtrend: it's below all five of its weekly moving averages, and 82% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over TLRY on returns for 2026, with the stronger performance.
TLRY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $162.8 | $85.9 | -47% |
| 2021 | $85.9 | $78.4 | -8.7% |
| 2022 | $78.4 | $27.9 | -64% |
| 2023 | $27.9 | $23.0 | -18% |
| 2024 | $23.0 | $14.3 | -38% |
| 2025 | $14.3 | $9.60 | -33% |
| 2026 YTD | $9.60 | $2.49 | -74% |
TLRY has finished every year since 2020 lower, and it's down 74% so far in 2026.